Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.38 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 2/20 | 0.37 |
| ▸ | F11 | P03951 | 2/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.37 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.37 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 4/20 | 0.35 |
| ▸ | CA2 | P00918 | 4/20 | 0.35 |
| ▸ | CA9 | Q16790 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | LPL | P06858 | 1/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20605342 | 0.88 | PARP1 (0.41) | PARP1CXCR2F2F11PRSS1 | |
| SCHEMBL29528340 | 0.86 | LMNA (0.45) | CXCR2F2F11PRSS1PRSS2 | |
| SCHEMBL19318869 | 0.86 | CXCR2 (0.38) | CXCR2LPLLIPGROCK1CES2 | |
| SCHEMBL30175604 | 0.86 | CXCR2 (0.38) | CXCR2LPLLIPGROCK1CES2 | |
| SCHEMBL1130939 | 0.86 | LMNA (0.45) | CXCR2F2F11PRSS1PRSS2 | |
| SCHEMBL20995735 | 0.85 | CXCR2 (0.38) | CXCR2F2F11PRSS1PRSS2 | |
| SCHEMBL2823437 | 0.83 | PARP1 (0.39) | PARP1CXCR2F2F11PRSS1 | |
| SCHEMBL1557557 | 0.83 | ALDH1A1 (0.39) | PARP1CXCR2F2F11PRSS1 | |
| SCHEMBL30753270 | 0.83 | PARP1 (0.39) | PARP1CXCR2F2F11PRSS1 | |
| SCHEMBL12068196 | 0.82 | ERN1 (0.37) | CXCR2LPLLIPGARROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767332-B2 | Glucose-sensitive albumin-binding derivatives | NOVO NORDISK A/S (DK) | 2023-09-26 | — | — | US | disclosed |
| EP-2027124-B1 | IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2013-07-03 | — | — | EP | disclosed |
| US-8178530-B2 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-15 | — | — | US | disclosed |
| US-8173656-B2 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-08 | — | — | US | disclosed |
| US-20110218178-A1 | IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | JANSSEN PHARMACEUTICA NV | 2011-09-08 | — | — | US | disclosed |
| US-20110092497-A1 | IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | JANSSEN PHARMACEUTICA NV | 2011-04-21 | — | — | US | disclosed |
| US-7893058-B2 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-22 | — | — | US | disclosed |
| EP-2027124-A1 | IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | Galapagos N.V. (BE) | 2009-02-25 | — | — | EP | disclosed |
| US-20070281943-A1 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-06 | — | — | US | disclosed |
| WO-2007131991-A1 | IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767332-B2 | Glucose-sensitive albumin-binding derivatives | ALB, DBI, FABP4 | PARP1 3715/4885CXCR2 2557/4885F2 2624/4885 |
| US-20110218178-A1 | IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IKZF3, IRAK2, IRAK1 | PARP1 3422/4885CXCR2 1241/4885F2 1965/4885 |
| US-20110092497-A1 | IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IKZF3, IRAK2, IRAK1 | PARP1 3422/4885CXCR2 1241/4885F2 1965/4885 |
| US-20070281943-A1 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | IKZF3, IRAK2, IRAK1 | PARP1 3422/4885CXCR2 1241/4885F2 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.